Literature DB >> 12548588

Bone cancer pain.

Denis R Clohisy1, Patrick W Mantyh.   

Abstract

BACKGROUND: Bone cancer pain is very common, and patients with this type of pain may be difficult to treat. Development of an experimental model for studying this condition is critical to advancing an understanding of the mechanisms that cause pain in patients with malignant disease.
METHODS: A murine model of bone cancer was studied. Combined analysis of the extent of tumor-induced bone destruction, pain, and neurochemical characterization of the peripheral and central nervous systems was performed to investigate bone cancer pain. Disease-induced bone destruction was assessed by radiographs and histomorphometry. Pain was assessed by spontaneous and elicited behaviors, and neurochemical analysis involved immunohistochemical detection of hyperalgesic peptides and neurochemical markers.
RESULTS: Mice with distal femoral sarcomas exhibited behavioral and neurochemical measures of pain. The pain condition created by malignant bone disease was distinct neurochemically from inflammatory and neuropathic pain states. Experimental evidence indicated that both disease-induced osteolysis and tumors themselves contributed to the generation of pain and that peripheral and central sensitization of the nervous system was present.
CONCLUSIONS: Malignant bone disease creates a unique pain state that involves sensitization of the nervous system. Major contributors to the pain state within the bone tissue are osteoclastic bone resorption and the malignant disease itself. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11144

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548588     DOI: 10.1002/cncr.11144

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

1.  Solitary painful osseous metastases: correlation of imaging features with pain palliation after radiofrequency ablation--a multicenter american college of radiology imaging network study.

Authors:  Jeffrey P Guenette; Michael J Lopez; Eunhee Kim; Damian E Dupuy
Journal:  Radiology       Date:  2013-05-08       Impact factor: 11.105

2.  Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma.

Authors:  Montserrat Ayala-Ramirez; J Lynn Palmer; Marie-Claude Hofmann; Maxine de la Cruz; Bryan S Moon; Steven G Waguespack; Mouhammed Amir Habra; Camilo Jimenez
Journal:  J Clin Endocrinol Metab       Date:  2013-02-22       Impact factor: 5.958

Review 3.  Bisphosphonates for advanced prostate cancer.

Authors:  Sascha Macherey; Ina Monsef; Franziska Jahn; Karin Jordan; Kwok Keung Yuen; Axel Heidenreich; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2017-12-26

Review 4.  [Diagnosis and therapy of tumor related pain].

Authors:  M Kloke
Journal:  Urologe A       Date:  2007-01       Impact factor: 0.639

5.  Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats.

Authors:  Ming-Hung Shih; Sheng-Chin Kao; Wei Wang; Myron Yaster; Yuan-Xiang Tao
Journal:  J Pain       Date:  2012-02-15       Impact factor: 5.820

6.  Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial.

Authors:  Zunyong Liu; Yan Xu; Zhong-Liang Liu; Yi-Zhou Tian; Xiao-Heng Shen
Journal:  Int J Clin Oncol       Date:  2017-05-08       Impact factor: 3.402

7.  Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons.

Authors:  Iryna A Khasabova; Yee Xiong; Lia G Coicou; Daniele Piomelli; Virginia Seybold
Journal:  J Neurosci       Date:  2012-09-12       Impact factor: 6.167

8.  A new rat model of bone cancer pain produced by rat breast cancer cells implantation of the shaft of femur at the third trochanter level.

Authors:  Qi Gui; Chengcheng Xu; Liang Zhuang; Shu Xia; Yu Chen; Ping Peng; Shiying Yu
Journal:  Cancer Biol Ther       Date:  2012-12-19       Impact factor: 4.742

9.  Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases.

Authors:  Kazuma Ogawa; Takahiro Mukai; Keiichi Kawai; Norito Takamura; Hirofumi Hanaoka; Kazuyuki Hashimoto; Kazuhiro Shiba; Hirofumi Mori; Hideo Saji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-16       Impact factor: 9.236

Review 10.  [Treatment strategies for pathological fractures of the spine].

Authors:  M Pishnamaz; V Quack; C Herren; F Hildebrand; P Kobbe
Journal:  Unfallchirurg       Date:  2021-08-03       Impact factor: 1.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.